Synthesis, Characterisation, Biological Evaluation and In Silico Studies of Quinoline–1,2,3-Triazole–Anilines as Potential Antitubercular and Anti-HIV Agents
Molecules · 2025
DOI: 10.3390/molecules30102119 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Snethemba S Magwaza und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Physics, University of KwaZulu Natal, Westville Campus, Durban 4001, South Africa. Hauptthemen laut MEDLINE: Antitubercular Agents, Triazoles, Anti-HIV Agents, Quinolines. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South African National Research Foundation (NRF) CSUR, South African National Research Foundation (NRF), South African Medical Research Council (MRC) Self-Initiated Research grant.
Abstract (Originalsprache)
HIV/AIDS and Mycobacterial tuberculosis (Mtb) are the leading cause of deaths worldwide. Thus, better medicaments are required to manage these diseases. Quinolines have shown great potential due to their broad spectrum of biological activity. Thus, quinoline–1,2,3-triazole–aniline hybrids were synthesised in moderate to good yields. Compounds 11g (IC50 = 0.388 µM), 11h (IC50 = 0.01032 µM) and 11i (IC50 = 0.167 µM) exhibited the most promising in vitro activities against the wild-type HIV-1 subtype B, with 11h being 9-fold more active than AZT (IC50 = 0.0909 µM), the reference drug. Furthermore, compound 11h displayed moderate activity, with a MIC90 of 88μM against Mtb’s H37Rv strain. Cytotoxicity studies on TZM-bl cell lines revealed that most of the tested compounds were generally non-cytotoxic; the selectivity index (SI) for 11h, the front runner, is >2472. Molecular docking studies revealed that 11h interacted with Phe112, Tyr108, Glu283 and Trp86 amino acid residues in the active site of HIV-1. DFT studies revealed that 11h has the ability to donate and accept electrons to and from available orbitals. The predicted ADMET studies showed that these compounds possess drug-likeness, and 11h has the potential for further optimisation as an anti-HIV-1 agent.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Physics, University of KwaZulu Natal, Westville Campus, Durban 4001, South Africa.
- HIV Pathogenesis Programme, Doris Duke Medical Research Institute, School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu Natal, Durban 4001, South Africa.
- Department of Chemical Sciences, Adekunle Ajasin University, Akungba-Akoko 342111, Nigeria.
- School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu Natal, Durban 4001, South Africa.
ORCID-Profile: Nompumelelo P Mkhwanazi, Matshawandile Tukulula
Förderung
- South African National Research Foundation (NRF) CSUR
- South African National Research Foundation (NRF)
- South African Medical Research Council (MRC) Self-Initiated Research grant
- UKZN
- Government of the Republic of Nigeria
Zitieren
APA
Magwaza, S. S., Naidu, D., Oyeneyin, O. E., Senzani, S., Mkhwanazi, N. P., & Tukulula, M. (2025). Synthesis, Characterisation, Biological Evaluation and In Silico Studies of Quinoline–1,2,3-Triazole–Anilines as Potential Antitubercular and Anti-HIV Agents. Molecules. https://doi.org/10.3390/molecules30102119
Vancouver
Magwaza SS, Naidu D, Oyeneyin OE, Senzani S, Mkhwanazi NP, Tukulula M. Synthesis, Characterisation, Biological Evaluation and In Silico Studies of Quinoline–1,2,3-Triazole–Anilines as Potential Antitubercular and Anti-HIV Agents. Molecules. 2025. doi:10.3390/molecules30102119
BibTeX
@article{Magwaza2025,
author = {Magwaza, Snethemba S and Naidu, Darian and Oyeneyin, Oluwatoba E and Senzani, Sibusiso and Mkhwanazi, Nompumelelo P and Tukulula, Matshawandile},
title = {Synthesis, Characterisation, Biological Evaluation and In Silico Studies of Quinoline–1,2,3-Triazole–Anilines as Potential Antitubercular and Anti-HIV Agents},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30102119}
}
EUVIMED